MNKD Stock Analysis: MannKind | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.209m USD | 12M Return: -31.6% | US56400P7069 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.9M
Qual. Beats: 0
Rev. Trend: 98.8%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
MannKind Corporation is a U.S. biopharmaceutical company headquartered in Danbury, Connecticut that develops and commercializes treatments for chronic diseases, including diabetes, pulmonary hypertension, and fluid overload associated with heart failure and chronic kidney disease. Its approved commercial products include Afrezza (inhaled insulin for glycemic control), Furoscix (furosemide injection for edema), V-Go (a mechanical basal-bolus insulin delivery system), and Tyvaso DPI (an inhaled powder for pulmonary hypertension). The company is also advancing a pipeline that includes MNKD-201 (a dry-powder formulation of nintedanib for idiopathic pulmonary fibrosis) and MNKD-701 (focused on bumetanide), and maintains partnerships with United Therapeutics, Thirona Bio, and Rose Pharma.
The business model reflects the typical structure of the biotechnology sector, where companies depend on lengthy drug development cycles, regulatory approvals, and intellectual property protection to bring therapies to market. MannKinds portfolio is built around its proprietary dry-powder inhalation and Technosphere drug-delivery technology, which underpins multiple products and pipeline candidates across therapeutic areas.
- Furoscix commercial uptake accelerates heart failure segment revenue
- Tyvaso DPI royalties from United Therapeutics boost top line
- GLP-1 competition pressures Afrezza inhaled insulin market share
| Net Income: -74.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.11 > 0.02 and ΔFCF/TA -19.63 > 1.0 |
| NWC/Revenue: 31.92% < 20% (prev 79.58%; Δ -47.66% < -1%) |
| CFO/TA -0.09 > 3% & CFO -66.5m > Net Income -74.8m |
| Net Debt (348.7m) to EBITDA (6.91m): 50.49 < 3 |
| Current Ratio: 2.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (320.2m) vs 12m ago 2.74% < -2% |
| Gross Margin: 76.05% > 18% (prev 75.18%; Δ 0.87% > 0.5%) |
| Asset Turnover: 67.92% > 50% (prev 63.44%; Δ 4.48% > 0%) |
| Interest Coverage Ratio: -0.37 > 6 (EBIT TTM -17.8m / Interest Expense TTM 48.1m) |
| A: 0.18 (Total Current Assets 240.5m - Total Current Liabilities 108.5m) / Total Assets 722.6m |
| B: -4.50 (Retained Earnings -3.25b / Total Assets 722.6m) |
| C: -0.03 (EBIT TTM -17.8m / Avg Total Assets 608.6m) |
| D: -0.05 (Book Value of Equity -37.3m / Total Liabilities 759.9m) |
| Altman-Z'' = -13.73 = D |
| DSRI: 1.65 (Receivables 41.0m/18.9m, Revenue 413.4m/313.8m) |
| GMI: 0.99 (GM 75.18% / 76.05%) |
| AQI: 6.30 (AQ_t 0.53 / AQ_t-1 0.08) |
| SGI: 1.32 (Revenue 413.4m / 313.8m) |
| TATA: -0.01 (NI -74.8m - CFO -66.5m) / TA 722.6m) |
| Beneish M = 0.87 (Cap -4..+1) = D |
As of November 09, 2026, the stock is trading at USD 3.90 with a total of 4,984,501 shares traded. Over the past week, the price has changed by +11.43%, over one month by +5.12%, over three months by +0.26% and over the past year by -31.58%.
Current recommended Stop Loss: 3.60 (which is 7.7% or 1.6 ATR below the current price).
MannKind has received a consensus analysts rating of 4.78. Therefore, it is recommended to buy MNKD.
- StrongBuy: 8
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 8.1 | 107.2% |
P/E Forward = 30.303
P/S = 3.0714
P/B = 187.8507
P/EG = 4.3866
Revenue TTM = 413.4m USD
EBIT TTM = -17.8m USD
EBITDA TTM = 6.91m USD
Long Term Debt = 318.4m USD (from longTermDebt, last fiscal year)
Short Term Debt = 12.7m USD (from shortTermDebt, last quarter)
Debt = 445.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 11.8m
Net Debt = 348.7m USD (calculated: Debt 445.3m - CCE 96.6m)
Enterprise Value = 1.56b USD (1.21b + Debt 445.3m - CCE 96.6m)
Interest Coverage Ratio = -0.37 (Ebit TTM -17.8m / Interest Expense TTM 48.1m)
EV/FCF = -19.80x (Enterprise Value 1.56b / FCF TTM -78.7m)
FCF Yield = -5.05% (FCF TTM -78.7m / Enterprise Value 1.56b)
FCF Margin = -19.04% (FCF TTM -78.7m / Revenue TTM 413.4m)
Net Margin = -18.10% (Net Income TTM -74.8m / Revenue TTM 413.4m)
Gross Margin = 76.05% ((Revenue TTM 413.4m - Cost of Revenue TTM 99.0m) / Revenue TTM)
Gross Margin QoQ = 76.92% (prev 72.99%)
Tobins Q-Ratio = 2.16 (Enterprise Value 1.56b / Total Assets 722.6m)
Interest Expense / Debt = 10.79% (Interest Expense 48.1m / Debt 445.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -14.0m (EBIT -17.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.22 (Total Current Assets 240.5m / Total Current Liabilities 108.5m)
Debt / Equity = -11.95 (negative equity) (Debt 445.3m / totalStockholderEquity, last quarter -37.3m)
Debt / EBITDA = 50.49 (Net Debt 348.7m / EBITDA 6.91m)
Debt / FCF = -4.43 (negative FCF - burning cash) (Net Debt 348.7m / FCF TTM -78.7m)
Total Stockholder Equity = -53.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.29% (Net Income -74.8m / Total Assets 722.6m)
RoE = 139.4% (negative equity) (Net Income TTM -74.8m / Total Stockholder Equity -53.7m)
RoCE = -6.71% (EBIT -17.8m / Capital Employed (Equity -53.7m + L.T.Debt 318.4m))
RoIC = -2.32% (negative operating profit) (NOPAT -14.0m / Invested Capital 606.1m)
WACC = 8.51% (E(1.21b)/V(1.65b) * Re(8.50%) + D(445.3m)/V(1.65b) * Rd(10.79%) * (1-Tc(0.21)))
Discount Rate = 8.50% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 75.90 | Cagr: 7.33%
[DCF] Fair Price = unknown (Cash Flow -78.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.45 | # QB: 0
Revenue Correlation: 98.75 | Revenue CAGR: 27.44% | SUE: -0.88 | # QB: -1
EPS current Quarter (2027-03-31): EPS=0.01 | Chg30d=N/A | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=0.03 | Chg30d=N/A | Revisions=-25% | GrowthEPS=-86.8% | GrowthRev=+26.6%
EPS next Year (2027-12-31): EPS=0.14 | Chg30d=+5.88% | Revisions=+25% | GrowthEPS=+440.0% | GrowthRev=+14.8%
[Analyst] Revisions Ratio: +0% (up=1, down=1)